Arvinas Inc. (ARVN) to Offer $250M in Common Stock

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC® Discovery Engine, today announced that it is commencing an underwritten public offering of $250.0 million of its common stock. In addition, Arvinas intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $37.5 million of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares are to be offered by Arvinas.

Goldman Sachs & Co. LLC and Piper Sandler & Co. are acting as joint book-running managers for the offering.

You May Also Be Interested In

• Goldman Sachs Adjust Monthly US Director's Cut List
• Henry Chuanyao Chen Goldman: From Curiosity to Capital – Building the Next Chapter of Fintech Innovation in Hong Kong
• TXNM Energy launches $400M common stock offering